The Lancet Regional Health publishes pivotal phase 3 clinical study on Miqnaf

Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities

AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials

Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing

Enveric clears FDA feedback milestone, prepares IND submission for EB-003

IND application for EB-003 expected in early 2026

Atom enrolls first patient in global phase 2 trial of ABP-745 for acute gout flares

ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo

Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy

This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options

Galimedix completes phase 1 study with oral small molecule GAL-101

The study further confirmed that GAL-101 effectively crosses the blood-brain barrier